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Abstract 
The unbalanced der(2)t(1;2)(q12-21;q37) is a rare 
anomaly in hematological malignancies with 
unknown clinical significance. 
Keywords 
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events. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), multiple myeloma 
(MM) and less frequently lymphoid malignancies. 
Phenotype/cell stem origin 
Myeloid malignancies  in 5 (3 males and 2 females): 
1 Fanconi anemia patient with refractory anemia 
(RA) (Huret et al., 1988), 1 AML (Raimondi et al 
1999), 1 acute myeloblastic leukemia with minimal 
differentiation (AML-M0) and 2 acute monoblastic 
leukemia patients (AML-M5) (Busson Le Coniat et 
al., 2000; Cerveira et al., 2012).  
Multiple myeloma in 8 (3 males and 5 females) 
(Smadja et al., 2001; Sawyer et al., 2014; Rack et al., 
2016). 
Partial karyotypes showing the unbalanced rearrangement between chromosomes 1 and 2. 
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Epidemiology 
10 males and 8 females aged 21 to 81 years (median 
69 years); male prevalence in patients with lymphoid 
malignancies (2 males in ALL and 3 males/1 female 
in lymphomas), aged 51, 69 and 71 years, 2 
unknown. Patient with myeloid malignancies were 
aged 21, 68, 77 and 81 years, 1 unknown; the age of 
MM patients is unknown. 
Prognosis 
The Fanconi anemia patient received androgen 
therapy. He developed refractory anemia 4 years 
later that was treated with corticosteroids and 
antibiotics, but after recurrent infections he died 
from pneumonia 4 years later. The patient with acute 
monoblastic leukemia and t(11;19)(q23;p13) was 
treated with chemotherapy but failed to achieve 
remission; after receiving allogenic bone marrow 
transplant he is alive 23+ months. 2 AML patients 
had highly complex karyotypes, considered as an 
adverse prognostic factor in AML. Similarly, in 
patients with MM or lymphoid malignancies and 




Unbalanced rearrangement resulting in 1q trisomy. 
Additional anomalies 
Found in association with del(5q) in MDS, 11q23/ 
KMT2A (MLL)/ MLLT1 in acute monoblastic 
leukemia, as an additional anomaly to t(9;22) in 1 
AML and in both ALL cases and as an additional 
aberration to t(14;18) in 2 lymphoma patients; found 
as part of highly complex karyotypes in the 
remaining patients. 




A non-random structural gain of 1q is a known 
structural anomaly in hematopoietic malignancies, 
and it is often the result of an unbalanced 
chromosome translocation. The breakpoints within 
1q show considerable variation from 1q11 to 1q43, 
with a clustering to 1q12-23. Various unbalanced 1q 
translocation partners have been described, among 
them, the der(2)t(1;2)(q12-21;q37) has been detected 
accompanied with other chromosome abnormalities, 
therefore it is likely a secondary genetic event. The 
major consequence of this unbalanced chromosome 
translocation is the genomic imbalance resulting  
 
from the gain of the long arm of chromosome 1q. 
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